Awiqli is a new insulin injection that needs to be administered only once a week. Learn from a doctor about benefits, side ...

India now offers Awiqli, a new once-weekly basal insulin for diabetes patients. This drug reduces annual injections from 365 ...

By Rishika Sadam July 9 (Reuters) - Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in ...

Novo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026. Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) ...

What Is Awiqli, and Why Does It Matter? Awiqli (insulin icodec-abae) is a once-weekly long-acting basal insulin injection approved by the FDA for adults with type 2 diabetes. It helps lower blood ...

If you have diabetes, you may be considering different treatment options to manage your blood sugar. One option you may hear about is Awiqli (insulin icodec). Awiqli is a once-weekly, long-acting ...

Data from the ONWARDS clinical trial program supported the efficacy of once-weekly insulin icodec-abae compared with daily basal insulin. The Food and Drug Administration (FDA) has approved Awiqli ® ...

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, ...

The Awiqli® approval reflects Novo Nordisk's ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- ...

PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the ...

The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 -- ...